Literature DB >> 30029891

For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough).

Stephen J Russell1.   

Abstract

Mesh：

Year:  2018        PMID： 30029891      PMCID： PMC6094866          DOI： 10.1016/j.ymthe.2018.07.003

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  40 in total

Review 1.  Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.

Authors:  Miguel-Angel Perales; Partow Kebriaei; Leslie S Kean; Michel Sadelain
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-13       Impact factor: 5.742

Review 2.  Original antigenic sin: A comprehensive review.

Authors:  Anup Vatti; Diana M Monsalve; Yovana Pacheco; Christopher Chang; Juan-Manuel Anaya; M Eric Gershwin
Journal:  J Autoimmun       Date:  2017-05-05       Impact factor: 7.094

Review 3.  Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy.

Authors:  A-Rum Yoon; Jinwoo Hong; Sung Wan Kim; Chae-Ok Yun
Journal:  Expert Opin Drug Deliv       Date:  2016-03-16       Impact factor: 6.648

4.  Rescue and propagation of fully retargeted oncolytic measles viruses.

Authors:  Takafumi Nakamura; Kah-Whye Peng; Mary Harvey; Suzanne Greiner; Ian A J Lorimer; Charles D James; Stephen J Russell
Journal:  Nat Biotechnol       Date:  2005-01-30       Impact factor: 54.908

Review 5.  Potential and clinical translation of oncolytic measles viruses.

Authors:  Steven Robinson; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2017-03       Impact factor: 4.388

6.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Authors:  Katrin Friedrich; Jan Rh Hanauer; Steffen Prüfer; Robert C Münch; Iris Völker; Christodoulos Filippis; Christian Jost; Kay-Martin Hanschmann; Roberto Cattaneo; Kah-Whye Peng; Andreas Plückthun; Christian J Buchholz; Klaus Cichutek; Michael D Mühlebach
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

7.  Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor.

Authors:  K-W Peng; P D Holler; B A Orr; D M Kranz; S J Russell
Journal:  Gene Ther       Date:  2004-08       Impact factor: 5.250

8.  Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins.

Authors:  Biljana Petrovic; Tatiana Gianni; Valentina Gatta; Gabriella Campadelli-Fiume
Journal:  PLoS Pathog       Date:  2017-04-19       Impact factor: 6.823

9.  Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.

Authors:  Hasan Rehman; Ann W Silk; Michael P Kane; Howard L Kaufman
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751

Review 10.  Designing and building oncolytic viruses.

Authors:  Justin Maroun; Miguel Muñoz-Alía; Arun Ammayappan; Autumn Schulze; Kah-Whye Peng; Stephen Russell
Journal:  Future Virol       Date:  2017-03-31       Impact factor: 1.831
View more
  3 in total

1.  Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors.

Authors:  Nicolas Çuburu; Lukasz Bialkowski; Sergio M Pontejo; Shiv K Sethi; Alexander T F Bell; Rina Kim; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-24       Impact factor: 12.779

2.  Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control.

Authors:  Ting-Miao Wu; Ji-Bin Liu; Yu Liu; Yi Shi; Wen Li; Gao-Ren Wang; Yu-Shui Ma; Da Fu
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

3.  Multiple Treatment Cycles of Neural Stem Cell Delivered Oncolytic Adenovirus for the Treatment of Glioblastoma.

Authors:  Jennifer Batalla-Covello; Hoi Wa Ngai; Linda Flores; Marisa McDonald; Caitlyn Hyde; Joanna Gonzaga; Mohamed Hammad; Margarita Gutova; Jana Portnow; Tim Synold; David T Curiel; Maciej S Lesniak; Karen S Aboody; Rachael Mooney
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.